Skip to content
Archive

KOLINPHARMA® has obtained the recognition of “Growth Leader 2025" for the sixth consecutive year

This year, too, Kolinpharma® was confirmed among the 500 Italian companies that stood out for the highest revenue growth in the 2020-2023 observation period, with a revenue CAGR of 24.02%, up 8 percentage points on the previous three-year observation period.

This is a list of the 500 Italian companies with the highest revenue growth in the three-year period 2020-2023 that took part in the call launched by Il Sole 24 Ore and Statista

The criteria considered:

Revenue of at least €100,000 in 2020

Revenue of at least €1.5 million in 2023

Being an independent Italian company

Meeting the principles of good repute

Nearly 1,000 companies applied. The data was checked by Statista

Another important milestone on KOLINPHARMA's successful journey!

Growth Leaders 2025 ranking

More news

  1. KOLINPHARMA® INCLUDED AMONG THE 100 ITALIAN EXCELLENCES
  2. KOLINPHARMA® has presented Declinex®, launching its new line of products dedicated to neurodegenerative diseases.
  3. Kolinpharma® for gender equality at PMIHeroes
Archive